Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Federal Drug Administration (2)
- Abigail Alliance (1)
- Athletes (1)
- Controlled Substances Act (1)
- Dietary Supplement Health & Education Act (1)
-
- Drug Companies (1)
- Drug regulation (1)
- FDA (1)
- First amendment (1)
- Free speech (1)
- HGH (1)
- Health Care (1)
- Health Law (1)
- Health law (1)
- Health regulation (1)
- Individual Rights (1)
- Jacobson (1)
- Jacobson v. Massachusetts (1)
- Labeling (1)
- Marketing (1)
- Medicine (1)
- Off-label (1)
- PED (1)
- Performance enhancing drugs (1)
- Physicians (1)
- Prescription Drugs (1)
- Public Health Right (1)
- School Board of Nassau County v. Arline (1)
- Smallpox (1)
- Sports law (1)
Articles 1 - 5 of 5
Full-Text Articles in Health Law and Policy
Off-Label Drug Marketing, The First Amendment, And Federalism, David Orentlicher
Off-Label Drug Marketing, The First Amendment, And Federalism, David Orentlicher
Scholarly Works
In this article, Professor Orentlicher explores free speech and federalism issues arising from FDA regulation of off-label uses and off-label marketing of drugs. In light of the FDA's desire to respect state government authority, together with other considerations discussed in this article, he argues for the rejection of the analysis of the Caronia court and to give the FDA significant leeway in its regulation of off-label marketing.
Ignorance, Harm, And The Regulation Of Performance-Enhancing Substances, Lisa Milot
Ignorance, Harm, And The Regulation Of Performance-Enhancing Substances, Lisa Milot
Scholarly Works
There is a disconnect between how legal and sporting authorities, on the one hand, and many elite athletes, on the other, view the use of performance-enhancing substances. While official and popular narratives portray the use of these substances as isolated examples of deviant behavior, to the elite athletes who daily push their bodies beyond societally normal limits of pain and risk, enhancement is oftentimes an accepted part of the job. As a result, efforts to regulate and detect athletes’ use of these substances have consistently captured only a small fraction of the use that exists.
This Article describes the ways …
Verify, Then Trust: How To Legalize Off-Label Drug Marketing, Fazal Khan, Justin Holloway
Verify, Then Trust: How To Legalize Off-Label Drug Marketing, Fazal Khan, Justin Holloway
Scholarly Works
This article will discuss the current state of off-label medicine, relevant legislation in the area, and a proposal designed to capture the benefits of off-label medicine while limiting its dangers when practiced perniciously. Part II will discuss the regulations in place governing off-label promotion and will detail the practice of ghostwriting and its associated concerns. Part III will analyze the costs and benefits of off-label marketing and practice of medicine, and will utilize a case study to demonstrate the predicament of drug manufacturers. Part IV will set forth a proposal to use the newly created Patient-Centered Outcomes Research Institute to …
The Commerical Speech Doctrine In Health Regulation: The Clash Between The Public Interest In A Robust First Amendment And The Public Interest In Effective Protection From Harm, David Orentlicher
Scholarly Works
No abstract provided.
The Public’S Right To Health: When Patient Rights Threaten The Commons, Elizabeth Weeks Leonard
The Public’S Right To Health: When Patient Rights Threaten The Commons, Elizabeth Weeks Leonard
Scholarly Works
This Article offers a contemporary examination of traditional public health objectives to address social problems not amenable to individual resolution. Taking the tradition a step further, it defines a "public health right" that may justify certain government actions that otherwise appear to impair individual rights. For example, lawmakers are considering whether current regulations on prescription drugs should be loosened to allow terminally ill patients to access drugs before they have been tested and approved for the general public. This Article concludes that expanding access to experimental drugs would violate the public health right to scientific knowledge and new drug development. …